Outcome comparison of pyrotinib with current standard of care in the second/third line setting in advanced non-small cell lung cancer patients with HER2 mutation.
Mao S, Luo L, Yang S, Wang Y, Zhou F, Yu J, Chen B, Gao G, Li X, Zhao C, Cheng L, Liu Y, Wang W, Jia K, Shao C, Liu X, Chen X, Su C, Zhou C, Wu F, Ren S.
Mao S, et al. Among authors: ren s.
Chin Med J (Engl). 2023 Apr 5;136(7):848-850. doi: 10.1097/CM9.0000000000002453.
Chin Med J (Engl). 2023.
PMID: 36921117
Free PMC article.
No abstract available.